Amazon is buying PillPack for $1 billion. Photo: PillPack

Amazon's $1 billion acquisition of mail-order pharmacy startup PillPack created an industry-wide frenzy, as prognosticators forecast doom for traditional pharmacies like Walgreens and Rite Aid. But Amazon still has a long way to go if it wants to drastically change the drug supply chain.

The big picture: Amazon is buying a small player in a highly regulated industry dominated by powerful incumbent companies that aren't willing to give up their turf. The online retailing giant will have to build or acquire more parts to make a big difference.

The unresolved issue: Payment. Uninsured people or patients willing to pay cash for their prescriptions can easily switch to PillPack, but that is a tiny part of the market.

  • Pharmacies need to be in the networks of pharmacy benefit managers (PBMs) — the middlemen of the drug supply chain — if they want to dispense drugs to most people.
  • The big PBMs often steer insured patients to their own mail-order pharmacies.
  • PillPack is an in-network pharmacy for all of the major PBMs, but its contract with Express Scripts may discontinue by the end of July.
  • A PillPack spokesperson said the company doesn't comment on negotiations. An Express Scripts spokesperson said, "If PillPack elects to terminate our agreement, we are committed to ensuring no gaps in care for patients."

The bottom line: Pharmacies are tethered to PBMs in the current system. That means Amazon will have to play ball with the big guns that often create favorable contracts for themselves, or "Amazon needs to buy a PBM (which is possible) to have a meaningful impact on market share," Ann Hynes of investment bank Mizuho Securities USA wrote in a note to Wall Street.

Yes, but: Amazon has 100 million Prime members who very well could demand their prescriptions be covered through Amazon's pharmacy.

  • "This is a multiyear, if not decade-long, chess game," pharmaceutical supply chain expert Stephen Buck said.

Flashback: Amazon used to own 40% of, an early iteration of an online pharmacy. But PBMs did not include in their networks, according to Steven Halper of financial firm Cantor Fitzgerald. So left the prescription business, was bought out by Walgreens, and then shut down in a matter of years.

Go deeper

Jul 29, 2020 - Technology

Bezos: No guarantee Amazon didn't exploit third-party seller data

Amazon CEO Jeff Bezos said Wednesday he can't guarantee employees have never used sales data from individual third-party sellers to develop the company's own products, despite a policy against that practice and past denials that Amazon engages in it.

Why it matters: Lawmakers and Amazon competitors and sellers have repeatedly hammered the e-commerce giant over accusations that Amazon accesses data on third-party sellers to boost its own house-label products. Bezos is admitting he can't rule out that this has happened.

Updated Jul 29, 2020 - Technology

Tech's major powers face heat during House antitrust hearing

Screenshot: CSPAN

Wednesday's House antitrust hearing with the CEOs of Facebook, Google, Amazon and Apple went down some politically fraught rabbit holes, but also saw tech's most powerful figures face sharper questions than they've seen before from Washington.

What's happening: Republicans slammed the companies for alleged anti-conservative bias, but Democrats largely narrowed their focus to possible competitive abuses, putting the CEOs on their back feet and producing some surprising admissions.

Jul 30, 2020 - Technology

House throws kitchen sink at tech CEOs

Illustration: Eniola Odetunde/Axios

House lawmakers aired an enormous array of grievances with the CEOs of Facebook, Google, Amazon and Apple Wednesday, throwing everything in their arsenal at four of the most powerful men in the world for six hours.

Quick take: The antitrust hearing didn't nail a case that these companies are harmful monopolies. But the representatives succeeded in wringing some surprising admissions from the executives about how they wield their market power, providing ammunition for regulators now conducting investigations — and possibly a spur for Congress to strengthen antitrust law for the digital era.